IMR Press / EJGO / Volume 20 / Issue 5-6 / pii/1999196

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

Lack of the predominant BRCAl and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction

Show Less
1 Department of Clinical Epidemiology, Tel Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
2 Susanne-Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Eur. J. Gynaecol. Oncol. 1999, 20(5-6), 371–372;
Published: 10 October 1999
Abstract

The objective of the present investigation was to assess the presence of BRCA mutations in ovarian carcinoma patients who were previously treated with fertility drugs. The presence of the predominant Jewish BRCAl and BRCA2 mutations in archival paraffin-embedded tumor tissue of four Jewish women with ovarian carcinoma who previously underwent ovulation induction with clomiphene citrate, was determined. None of the tissues contained the mutations examined. This preliminary finding does not support the assumption that the presence of BRCAl and BRCA2 mutations in some infertility patients treated by fertility drugs could explain the subsequent development of epithelial ovarian cancer in these women.

Keywords
Ovarian carcinoma
BRCA mutations
Ovulation induction
Clomiphene citrate
Share
Back to top